

## Annexes

### Annex A: Implications/Anticipated impact

- **Risk implication and mitigation.** There is some uncertainty regarding data availability for a number of the candidates, such as around disease burden, licensure timelines or a clear vaccination policy. The Secretariat will consult with relevant experts to ensure that analyses are informed by latest evidence. Outputs of these analyses will include clear explanations of any drivers of uncertainty. Risks related to specific VIS investment recommendations will be reflected in future papers.
- **Impact on countries.** Impact in Gavi countries is a key criterion in deciding on new vaccines. All vaccines under consideration have potential for public health impact in Gavi countries. The evaluation criteria also include indicators around implementation feasibility, to capture the potential additional needs or challenges that new vaccines with novel delivery strategies might pose in countries. If the menu is expanded, financial sustainability considerations will be even more critical for country decisions to access support for a new vaccine.
- **Impact on Alliance.** The VIS is an Alliance-wide process with significant stakeholder engagement. This will include extensive consultations with Board members and technical stakeholders from across the Alliance. VIS recommendations will consider roles and responsibilities of Alliance partners in the implementation of new programmes.
- **Legal and governance implications.** There are no legal implications with respect to the recommendations presented in this report.